On April 13, 2026, Revolution Medicines, Inc. reported successful Phase 3 trial results for daraxonrasib, showing median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. The treatment demonstrated statistically significant improvements in progression-free survival and overall survival, and the company plans to submit the data to regulatory authorities for a New Drug Application.